{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:29:40Z","timestamp":1789151380547,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"DOI":"10.7759\/cureus.90106","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T21:30:10Z","timestamp":1755207010000},"source":"Crossref","is-referenced-by-count":3,"title":["Immune Checkpoint Inhibitor-Induced Myositis Myocarditis and Myasthenia Gravis (MMM) Overlap Syndrome in a Rural District General Hospital: An Institutional Case Series Involving Four Patients"],"prefix":"10.7759","author":[{"given":"Umar","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeta E","family":"Both","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini A","year":"2013","unstructured":"Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013, 2013:857519. 10.1155\/2013\/857519","journal-title":"Scientifica (Cairo)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey JD","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021, 23:39. 10.1208\/s12248-021-00574-0","journal-title":"AAPS J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long L","year":"2018","unstructured":"Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, Chen H. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018, 9:176-89. 10.18632\/genesandcancer.180","journal-title":"Genes Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0419","article-title":"Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis","volume":"22","author":"Nishijima TF","year":"2017","unstructured":"Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017, 22:470-9. 10.1634\/theoncologist.2016-0419","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak R","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021, 26:1052-61. 10.1002\/onco.13931","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen J","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, et al.. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022, 33:1217-38. 10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/07357907.2022.2108827","article-title":"Adverse events induced by nivolumab plus ipilimumab vs. Nivolumab monotherapy among cancer patients: a systematic review and meta-analysis","volume":"40","author":"Kamat S","year":"2022","unstructured":"Kamat S, Patel J, Brown BR, Vyas A. Adverse events induced by nivolumab plus ipilimumab vs. Nivolumab monotherapy among cancer patients: a systematic review and meta-analysis. Cancer Invest. 2022, 40:777-88. 10.1080\/07357907.2022.2108827","journal-title":"Cancer Invest"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49867","article-title":"Exploring pembrolizumab-induced myocarditis, myositis, and myasthenia gravis: a comprehensive literature review and case presentation on bladder cancer","volume":"15","author":"Shah D","year":"2023","unstructured":"Shah D, Young K. Exploring pembrolizumab-induced myocarditis, myositis, and myasthenia gravis: a comprehensive literature review and case presentation on bladder cancer. Cureus. 2023, 15:e49867. 10.7759\/cureus.49867","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho A","year":"2025","unstructured":"S\u00e1nchez-Camacho A, Torres-Zurita A, Gallego-L\u00f3pez L, et al.. Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review. Front Immunol. 2025, 16:1597259. 10.3389\/fimmu.2025.1597259","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki O","year":"2020","unstructured":"Kooshkaki O, Derakhshani A, Hosseinkhani N, et al.. Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials. Int J Mol Sci. 2020, 21:4427. 10.3390\/ijms21124427","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe DN","year":"2024","unstructured":"Lipe DN, Qdaisat A, Krishnamani PP, et al.. Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review. Diagnostics (Basel). 2024, 14:1794. 10.3390\/diagnostics14161794","journal-title":"Diagnostics (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14080764","article-title":"Unravelling the acute, chronic and steroid-refractory management of high-grade neurological immune-related adverse events: a call to action","volume":"14","author":"Malvaso A","year":"2024","unstructured":"Malvaso A, Giglio P, Diamanti L, et al.. Unravelling the acute, chronic and steroid-refractory management of high-grade neurological immune-related adverse events: a call to action. Brain Sci. 2024, 14:764. 10.3390\/brainsci14080764","journal-title":"Brain Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.76834","article-title":"Triple M overlap syndrome: myocarditis, myositis and myasthenia gravis after a single administration of pembrolizumab","volume":"17","author":"Baptista C","year":"2025","unstructured":"Baptista C, Margarido I, Bizarro R, Branco FP, Faria A. Triple M overlap syndrome: myocarditis, myositis and myasthenia gravis after a single administration of pembrolizumab. Cureus. 2025, 17:e76834. 10.7759\/cureus.76834","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10264-0","article-title":"Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review","volume":"268","author":"Lotan I","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I. Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol. 2021, 268:4573-86. 10.1007\/s00415-020-10264-0","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03313-3","article-title":"Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis","volume":"26","author":"Lu HR","year":"2024","unstructured":"Lu HR, Zhu PF, Deng YY, Chen ZL, Yang L. Predictive value of NLR and PLR for immune-related adverse events: a systematic review and meta-analysis. Clin Transl Oncol. 2024, 26:1106-16. 10.1007\/s12094-023-03313-3","journal-title":"Clin Transl Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang W","year":"2023","unstructured":"Zhang W, Tan Y, Li Y, Liu J. Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2023, 14:1234142. 10.3389\/fimmu.2023.1234142","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79397-6","article-title":"Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events","volume":"11","author":"Matsukane R","year":"2021","unstructured":"Matsukane R, Watanabe H, Minami H, et al.. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Sci Rep. 2021, 11:1324. 10.1038\/s41598-020-79397-6","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.631949","article-title":"Immune-related adverse events predict the efficacy of immune checkpoint inhibitors in lung cancer patients: a meta-analysis","volume":"11","author":"Wang D","year":"2021","unstructured":"Wang D, Chen C, Gu Y, et al.. Immune-related adverse events predict the efficacy of immune checkpoint inhibitors in lung cancer patients: a meta-analysis. Front Oncol. 2021, 11:631949. 10.3389\/fonc.2021.631949","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.004","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael Y","year":"2022","unstructured":"Hailemichael Y, Johnson DH, Abdel-Wahab N, et al.. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022, 40:509-523.e6. 10.1016\/j.ccell.2022.04.004","journal-title":"Cancer Cell"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/391020-immune-checkpoint-inhibitor-induced-myositis-myocarditis-and-myasthenia-gravis-mmm-overlap-syndrome-in-a-rural-district-general-hospital-an-institutional-case-series-involving-four-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T21:30:11Z","timestamp":1755207011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/391020-immune-checkpoint-inhibitor-induced-myositis-myocarditis-and-myasthenia-gravis-mmm-overlap-syndrome-in-a-rural-district-general-hospital-an-institutional-case-series-involving-four-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.90106","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}